Glucagon-Like Peptide-1 Promotes Islet Cell Growth and Inhibits Apoptosis in Zucker Diabetic Rats
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
A constant remodeling of islet cell mass mediated by proliferative and apoptotic stimuli ensures a dynamic response to a changing demand for insulin. In this study, we investigated the effect of glucagon-like peptide-1 (GLP-1) in Zucker diabetic rats, an animal model in which the onset of diabetes occurs when the proliferative potential and the rate of β-cell apoptosis no longer compensate for the increased demand for insulin. We subjected diabetic rats to a 2-d infusion of GLP-1 and tested their response to an ip glucose tolerance test. GLP-1 produced a significant increase of insulin secretion, which was paralleled by a decrease in plasma glucose levels (P < 0.001 and P < 0.01, respectively). Four days after the removal of the infusion pumps, rats were killed and the pancreas harvested to study the mechanism by which GLP-1 ameliorated glucose tolerance. Ex vivo immunostaining with the marker of cell proliferation, Ki-67, showed that the metabolic changes observed in rats treated with GLP-1 were associated with an increase in cell proliferation of the endocrine and exocrine component of the pancreas. Terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end-labeling staining, a marker of cellular apoptosis, indicated a reduction of apoptotic cells within the islet as well in the exocrine pancreas in GLP-1-treated rats. Double immunostaining for the apoptotic marker caspase-3 and for insulin showed a significant reduction of caspase-3 expression and an increase in insulin content in GLP-1-treated animals. Finally, staining of pancreatic sections with the nuclear dye 4,6-Diaminidino-2-phenyl-dihydrochloride demonstrated a marked reduction of fragmented nuclei in the islet cells of rats treated with GLP-1. Our findings provide evidence that the beneficial effects of GLP-1 in Zucker diabetic rats is mediated by an increase in islet cell proliferation and a decrease of cellular apoptosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies to date that have reported an increase in β-cell mass with glucagon-like peptide 1 (GLP-1)-1 based therapies were undertaken in young rodents (17–21).”
From Age-Dependent Decline in β-Cell Proliferation Restricts the Capacity of β-Cell Regeneration in Mice (2009) · cites this paper as [17]
Citations
Cites
Xu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Thorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906
Vilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884
Gutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868
Pick, A., Clark, J., Kubstrup, C., Levisetti, M., Pugh, W., Bonner-Weir, S., & Polonsky, K. S. (1998) · Diabetes · doi:10.2337/diabetes.47.3.358 · Cited by 551
FEHMANN, H.-C., GÖKE, R., & GÖKE, B. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-3-390 · Cited by 528
Perfetti, R. (2000) · Endocrinology · doi:10.1210/en.141.12.4600 · Cited by 442
Self-citationApoptosis Participates in the Remodeling of the Endocrine Pancreas in the Neonatal Rat
Scaglia, L. (1997) · Endocrinology · doi:10.1210/en.138.4.1736 · Cited by 418
β-Cell Mass Dynamics in Zucker Diabetic Fatty Rats
Finegood, D. T., McArthur, M. D., Kojwang, D., Thomas, M. J., Topp, B. G., Leonard, T., & Buckingham, R. E. (2001) · Diabetes · doi:10.2337/diabetes.50.5.1021 · Cited by 374
Research works printed but not linked: 2
- Nauck, 1993, Normalization of fasting hyperglycemia by exogenous glucagon-like peptide-1 [7–36 amide] in type 2 (non-insulin dependent) diabetic patients, Diabetologia, 36, 741, 10.1007/BF00401145 · DOI · Paper page
- Weibel, 1978, Stereologic methods. In: Practical methods for biologic morphometry, London: Academic Press; vol, 1, 101
Cited by
Items 101–200 of 505
Froud, T., Faradji, R. N., Pileggi, A., Messinger, S., Baidal, D. A., Ponte, G. M., Cure, P. E., Monroy, K., Mendez, A., Selvaggi, G., et al. (2008) · Transplantation · doi:10.1097/tp.0b013e31817c4ab3 · Cited by 84
Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide
Candeias, E. M. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i6.807 · Cited by 83
Mao, G.-H., Chen, G.-A., Bai, H.-Y., Song, T.-R., & Wang, Y.-X. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2008.12.030 · Cited by 86
“GLP-1 could enhance proliferation and inhibit apoptosis of islet cells [21].”
Evolution of Exenatide as a Diabetes Therapeutic
Bhavsar, S., Mudaliar, S., & Cherrington, A. (2013) · Current Diabetes Reviews · doi:10.2174/157339913805076472 · Cited by 81
DPP4 Inhibitors: a new approach in diabetes treatment
Doupis, J., & Veves, A. (2008) · Advances in Therapy · doi:10.1007/s12325-008-0076-1 · Cited by 95
Lee, S., & Lee, D. Y. (2017) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2017.22.1.15 · Cited by 79
“The cleaved fragment (9-36) does not exert insulinotropic effects.”
BackgroundKatagiri, D., Hamasaki, Y., Doi, K., Okamoto, K., Negishi, K., Nangaku, M., & Noiri, E. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013020134 · Cited by 80
Zhang, H., Zhang, X., Hu, C., & Lu, W. (2012) · Kidney and Blood Pressure Research · doi:10.1159/000337929 · Cited by 79
Zhang, J., Tokui, Y., Yamagata, K., Kozawa, J., Sayama, K., Iwahashi, H., Okita, K., Miuchi, M., Konya, H., Hamaguchi, T., et al. (2007) · Diabetologia · doi:10.1007/s00125-007-0737-6 · Cited by 84
“More recent studies have demonstrated that administration of GLP-1 inhibits beta cell apoptosis via the PI3-K–PKB signalling pathway [10–12].”
BackgroundGlucagon-like peptide 1: evolution of an incretin into a treatment for diabetes
D’Alessio, D. A., & Vahl, T. P. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00014.2004 · Cited by 80
“In addition, there is now evidence that GLP-1 inhibits -cell apoptosis, another action that would promote expansion of -cell mass (28, 45, 97).”
BackgroundHe, Y., Sadler, B. M., Sabo, R., Balez, S., Wang, Y., Campestrini, J., Laurent, A. L., Ligueros‐Saylan, M., & Howard, D. (2007) · Clinical Pharmacokinetics · doi:10.2165/00003088-200746090-00006 · Cited by 76
Moritoh, Y., Takeuchi, K., Asakawa, T., Kataoka, O., & Odaka, H. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.04.018 · Cited by 79
Glucagon-like peptide-1 and glucagon-like peptide-2
Baggio, L. L., & Drucker, D. J. (2004) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2004.08.001 · Cited by 84
Metabolic hormones are integral regulators of female reproductive health and function
Athar, F., Karmani, M., & Templeman, N. M. (2024) · Bioscience Reports · doi:10.1042/bsr20231916 · Cited by 91
“GLP-1 also promotes the proliferation of β -cells [272,273] and prevents their apoptosis [274].”
BackgroundGLP-1 inhibition of pancreatic islet cell apoptosis
Urusova, I. A., Farilla, L., Hui, H., D'Amico, E., & Perfetti, R. (2003) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2003.11.006 · Cited by 77
Self-citationRole of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus
León, D. D. D., Crutchlow, M. F., Ham, J.-Y. N., & Stoffers, D. A. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.07.011 · Cited by 94
A Review of Islet of Langerhans Degeneration in Rodent Models of Type 2 Diabetes
Nugent, D., Smith, D. M., & Jones, H. B. (2008) · Toxicologic Pathology · doi:10.1177/0192623308318209 · Cited by 87
“It is possible to prevent the reduction in β-cell mass by up-regulation of the β-cell growth factor, glucagon-like peptide 1, (Farilla et al., 2002; Sudre et al., 2002), and thereby, delay the onset of diabetes.”
Anti-inflammatory role of DPP-4 inhibitors in a nondiabetic model of glomerular injury
Higashijima, Y., Tanaka, T., Yamaguchi, J., Tanaka, S., & Nangaku, M. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00590.2014 · Cited by 69
“In experimental models of diabetes, GLP-1R stimulation not only reduced blood glucose but improved pancreatic islet function through proliferative and antiapoptotic effects on -cells (4, 10, 21).”
BackgroundDehghan, F., Soori, R., Gholami, K., Abolmaesoomi, M., Yusof, A., Muniandy, S., Heidarzadeh, S., Farzanegi, P., & Azarbayjani, M. A. (2016) · Scientific Reports · doi:10.1038/srep37819 · Cited by 72
Natalicchio, A., Labarbuta, R., Tortosa, F., Biondi, G., Marrano, N., Peschechera, A., Carchia, E., Orlando, M. R., Leonardini, A., Cignarelli, A., et al. (2013) · Diabetologia · doi:10.1007/s00125-013-3028-4 · Cited by 79
“Administration of GLP-1 was associated with proliferative and antiapoptotic effects in both endocrine and exocrine compartments of the pancreas [43, 44], and significantly reduced apoptotic beta cells in experimental diabetes models [45].”
BackgroundNeuropeptide Y promotes β-cell replication via extracellular signal-regulated kinase activation
Cho, Y. R., & Kim, C. W. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.12.170 · Cited by 78
Yang, M., Zhang, L., Wang, C., Liu, H., Boden, G., Yang, G., & Li, L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048392 · Cited by 67
Maiztegui, B., Borelli, M. I., Madrid, V., Zotto, H. H. D., Raschia, M. A., Francini, F., Massa, M. L., Flores, L. E., Rebolledo, O. R., & Gagliardino, J. J. (2010) · Clinical Science · doi:10.1042/cs20100372 · Cited by 73
Preservation of β-cell function by targeting β-cell mass
DEKONING, E., Bonner‐Weir, S., & Rabelink, T. J. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.02.001 · Cited by 84
Mudaliar, S. R. D., & Henry, R. R. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.12.006 · Cited by 73
Davies, M. J., Kela, R., & Khunti, K. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01330.x · Cited by 66
Sharma, A. N., Ligade, S. S., Sharma, J. N., Shukla, P., Elased, K. M., & Lucot, J. B. (2015) · Metabolic Brain Disease · doi:10.1007/s11011-014-9591-7 · Cited by 66
“GLP-1 is also known for β-cell proliferation and inhibition of pancreatic β-cell apoptosis (Farilla et al. 2002) and small bowel motility and gastric emptying (Tolessa et al. 1998).”
BackgroundFeng, A. L., Xiang, Y., Gui, L., Kaltsidis, G., Feng, Q., & Lu, W.-Y. (2017) · Diabetologia · doi:10.1007/s00125-017-4239-x · Cited by 74
Peptide‐based multi‐agonists: a new paradigm in metabolic pharmacology
Brandt, S. J., Müller, T. D., DiMarchi, R. D., Tschöp, M. H., & Stemmer, K. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12837 · Cited by 65
Sharma, A., & Verma, S. (2020) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2019.09.003 · Cited by 65
Kong, F., Wu, J., Sun, S., Ma, L., & Zhou, J. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.001 · Cited by 69
“GLP-1R stimulation not only enhances glucose-dependent insulin secretion and insulin gene expression in pancreatic b-cells, but also induces bcells proliferation and inhibits b-cells apoptosis (Farilla et al., 2002; Salehi et al., 2010).”
The physiological role of the brain GLP-1 system in stress
Holt, M. K., & Trapp, S. (2016) · Cogent Biology · doi:10.1080/23312025.2016.1229086 · Cited by 63
“In addition, peripheral GLP-1 has proliferative and protective effects on islet cells and inhibits gastric emptying (Egan, Bulotta, Hui, & Perfetti, 2003; Farilla et al., 2002; Nauck et al., 1997).”
BackgroundIncretin Hypersecretion in Post-Gastric Bypass Hypoglycemia—Primary Problem or Red Herring?
Vella, A., & Service, F. J. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2260 · Cited by 63
Gastrointestinal hormones and the regulation of β‐cell mass
Lavine, J. A., & Attie, A. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05802.x · Cited by 63
Pei, Z., Li, X., Longenecker, K. L., von Geldern, T. W., Wiedeman, P. E., Lubben, T. H., Zinker, B. A., Stewart, K. D., Ballaron, S. J., Stashko, M. A., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm051283e · Cited by 67
Natalicchio, A., De Stefano, F., Orlando, M. R., Melchiorre, M., Leonardini, A., Cignarelli, A., Labarbuta, R., Marchetti, P., Perrini, S., Laviola, L., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1166 · Cited by 60
Islet cell plasticity and regeneration
Migliorini, A., Bader, E., & Lickert, H. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2014.01.010 · Cited by 71
“Additionally, endogenous expression of Glp-1 in murine models of streptozotocin (STZ)induced diabetes has been shown to prevent hyperglycemia and to improve β-cell survival [75–77].”
BackgroundSite‐specific PEGylation of exenatide analogues markedly improved their glucoregulatory activity
Gong, N., Ma, A., Zhang, L., Luo, X., Zhang, Y., Xu, M. K., & Wang, Y. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01227.x · Cited by 63
“…DOI:10.1111/j.1476-5381.2011.01227.x www.brjpharmacol.org British Journal of Pharmacology (2011) 163 399–412 399© 2011 The Authors British Journal of Pharmacology © 2011 The British Pharmacological Society b-cell proliferation and islet neogenesis in diabetic animals (Farilla et al., 2002).”
BackgroundInfluentialStonehouse, A. H., Darsow, T., & Maggs, D. G. (2012) · Journal of Diabetes · doi:10.1111/j.1753-0407.2011.00143.x · Cited by 69
“of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia–reperfusion injury in rat heart.”
BackgroundKendall, D. M., Cuddihy, R. M., & Bergenstal, R. M. (2009) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2009.05.009 · Cited by 69
GLP-1 and type 2 diabetes: physiology and new clinical advances
Combettes, M. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.08.003 · Cited by 69
Glucagon-like peptide-1 protects mesenteric endothelium from injury during inflammation
Dozier, K. C., Cureton, E. L., Kwan, R. O., Curran, B., Sadjadi, J., & Victorino, G. P. (2009) · Peptides · doi:10.1016/j.peptides.2009.06.019 · Cited by 58
“Injury to myocytes and pancreatic beta-cells after an ischemic insult is attenuated by GLP-1 [3,12,13,33].”
Glucose‐dependent insulinotropic polypeptide signaling in pancreatic β‐cells and adipocytes
McIntosh, C. H., Widenmaier, S., & Kim, S. (2012) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2012.00196.x · Cited by 57
Antwi, K., Nicolas, G., Fani, M., Heye, T. J., Pattou, F. N., Grossman, A. B., Chanson, P., Reubi, J. C., Perren, A. A., Gloor, B., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02754 · Cited by 65
Kalra, S., Das, A. K., Sahay, R. K., Baruah, M. P., TIWASKAR, M. H., Das, S., Chatterjee, S., Saboo, B., Bantwal, G., Bhattacharya, S., et al. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0669-4 · Cited by 72
Aston-Mourney, K., Hull, R. L., Zraika, S., Udayasankar, J., Subramanian, S. L., & Kahn, S. E. (2011) · Diabetologia · doi:10.1007/s00125-011-2143-3 · Cited by 56
“Beta cell proliferation has been shown to increase with exendin-4 treatment in many [19, 40], but not all, rodent studies [40, 41].”
Zinc as a Potential Coadjuvant in Therapy for Type 2 Diabetes
Ruz, M., Carrasco, F., Rojas, P., Codoceo, J., Inostroza, J., Basfi-fer, K., Valencia, A., Vásquez, K. Y., Galgani, J. E., Pérez, Á., et al. (2013) · Food and Nutrition Bulletin · doi:10.1177/156482651303400210 · Cited by 63
No evidence of drug‐induced pancreatitis in rats treated with exenatide for 13 weeks
Tatarkiewicz, K., Belanger, P., Gu, G., Parkes, D., & Roy, D. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12040 · Cited by 56
Treatment of Type 1 Diabetic Patients with Glucagon-Like Peptide-1 (GLP-1) and GLP-1R Agonists
Kielgast, U., Holst, J., & Madsbad, S. (2009) · Current Diabetes Reviews · doi:10.2174/157339909789804413 · Cited by 56
“In rodent models of type 2 diabetes or insulin resistance, GLP-1 has been shown to promote ß-cell neogenesis, proliferation and differentiation and inhibit apoptosis in vivo, thereby increasing ß-cell mass [25-32].”
Fujii, Y., Osaki, N., Hase, T., & Shimotoyodome, A. (2015) · Journal of Nutritional Science · doi:10.1017/jns.2014.71 · Cited by 55
Liraglutide in clinical practice: dosing, safety and efficacy: Liraglutide in practice
Peterson, G. E., & Pollom, R. D. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02498.x · Cited by 55
Complications of Diabetes Therapy
Corathers, S. D., Peavie, S., & Salehi, M. (2013) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.06.005 · Cited by 65
Özyazgan, S., Kutluata, N., Afşar, S., Özdaş, Ş. B., & Akkan, A. G. (2005) · Pharmacology · doi:10.1159/000084277 · Cited by 55
Ghazi, T., Rink, L., Sherr, J. L., & Herold, K. C. (2014) · Diabetes Care · doi:10.2337/dc13-1169 · Cited by 54
“Moreover, animal studies have suggested that GLP-1 therapy may promote the proliferation of b-cells, enhance b-cell recovery, and suppress b-cell apoptosis (9,10), suggesting that there may be long-term primary benefit to its use.”
Antiapoptotic Actions of Exendin-4 against Hypoxia and Cytokines Are Augmented by CREB
Velmurugan, K., Balamurugan, A. N., Loganathan, G., Ahmad, A., Hering, B. J., & Pugazhenthi, S. (2012) · Endocrinology · doi:10.1210/en.2011-1895 · Cited by 53
“Administration of GLP-1 in animal models of diabetes has been shown to decrease -cell apoptosis (27, 28).”
Shirakawa, J., Amo, K., Ohminami, H., Orime, K., Togashi, Y., Ito, Y., Tajima, K., Koganei, M., Sasaki, H., Takeda, E., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.217216 · Cited by 59
Biswas, S. C., Buteau, J., & Greene, L. A. (2008) · Neurochemical Research · doi:10.1007/s11064-008-9646-4 · Cited by 55
Glucagon-Like Peptide 1 Analogs and their Effects on Pancreatic Islets
Tudurí, E., López, M., Diéguez, C., Nadal, Á., & Nogueiras, R. (2016) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2016.03.004 · Cited by 56
“Native GLP-1 has been shown to exert direct antiapoptotic effects on human [74] and rodent [56] b cells.”
BackgroundFiorentino, T. V., Casiraghi, F., Davalli, A. M., Finzi, G., La Rosa, S., Higgins, P. B., Abrahamian, G. A., Marando, A., Sessa, F., Perego, C., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.93091 · Cited by 51
Beyond glycemia: Comparing tirzepatide to GLP-1 analogues
Andraos, J., Muhar, H. K., & Smith, S. R. (2023) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-023-09825-1 · Cited by 59
“GLP-1 has also been shown to protect beta cells from apoptosis and stimulate beta-cell proliferation [10, 11].”
BackgroundPancreatic islet dysfunction in type 2 diabetes: a rational target for incretin-based therapies
Meece, J. (2007) · Current Medical Research and Opinion · doi:10.1185/030079906x167336 · Cited by 50
Faradji, R. N., Froud, T., Messinger, S., Monroy, K., Pileggi, A., Mineo, D., Tharavanij, T., Mendez, A. J., Ricordi, C., & Alejandro, R. (2009) · Cell Transplantation · doi:10.3727/096368909x474456 · Cited by 52
Wei, J., Ding, D., Wang, T., Liu, Q., & Lin, Y. (2017) · The FASEB Journal · doi:10.1096/fj.201700282r · Cited by 50
“Glp1 prevented the loss of islet b cells under diabetic condition by inhibiting apoptosis and enhancing proliferation via binding to its receptor (Glp1r) in islets (45).”
BackgroundHamed, K. M., Alosaimi, M. N., Ali, B. A., Alghamdi, A. M., Alkhashi, T., Alkhaldi, S. S., Altowarqi, N. A., Alzahrani, H., Alshehri, A., Alkhaldi, R. K., et al. (2024) · Cureus · doi:10.7759/cureus.68390 · Cited by 96
“Furthermore, it is worth noting that these agonists actively encourage the proliferation of β -cells and inhibit apoptosis, which has the potential to slow the onset of T2DM [42].”
BackgroundAoki, K., Masuda, K., Miyazaki, T., Togashi, Y., & Terauchi, Y. (2010) · Endocrine Journal · doi:10.1507/endocrj.k10e-103 · Cited by 48
“Since active GLP-1 reportedly promotes islet cell growth and inhibits apoptosis in an animal model [9], the increase in active GLP-1 in the M and S groups and the further increase in the M+S group might be beneficial for preserving β cells and reducing the development of diabetes in humans.”
BackgroundZhang, Z., Hu, Y., Xu, N., Zhou, W., Yang, L., Chen, R., Yang, R., Sun, J. M., & Chen, H. (2019) · Journal of Diabetes Research · doi:10.1155/2019/2583047 · Cited by 47
“Numerous studies have shown that infusion of GLP1 can efficiently ameliorate hyperglycemia in diabetic models [13, 14].”
BackgroundKarunakaran, U., Kim, H., Kim, J.-Y., & Lee, I. (2011) · Experimental Diabetes Research · doi:10.1155/2012/639762 · Cited by 53
“[95] L.”
BackgroundDixit, T. S., Sharma, A. N., Lucot, J. B., & Elased, K. M. (2013) · Physiology & Behavior · doi:10.1016/j.physbeh.2013.03.008 · Cited by 46
“In the pancreas GLP-1 causes β-cell proliferation and also inhibits β-cell apoptosis [3].”
Pathophysiology of diabetes mellitus type 2: beyond the duo "insulin resistance-secretion deficit".
Boada, C. A. C., & Martínez-Moreno, J. M. (2013) · PubMed · doi:10.3305/nh.2013.28.sup2.6717 · Cited by 79
Type 1 Diabetes Treatment beyond Insulin: Role of GLP-1 Analogs
Harrison, L. B., Mora, P. F., Clark, G. O., & Lingvay, I. (2013) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e318279b7d6 · Cited by 46
The regulation of pre- and post-maturational plasticity of mammalian islet cell mass
Mezza, T., & Kulkarni, R. (2014) · Diabetologia · doi:10.1007/s00125-014-3251-7 · Cited by 49
“GLP-1 promotes beta cell proliferation, islet neogenesis and beta cell survival in vivo [104], while GIP promotes beta cell survival in vivo but only promotes beta cell proliferation in vitro [105].”
BackgroundAnti-incretin, Anti-proliferative Action of Dopamine on β-Cells
Maffei, A., Segal, A. M., Álvarez-Pérez, J. C., García-Ocaña, A., & Harris, P. E. (2015) · Molecular Endocrinology · doi:10.1210/me.2014-1273 · Cited by 50
Insulin Resistance: A Potential New Target for Therapy in Patients with Heart Failure
Wong, A., AlZadjali, M. A., Choy, A. M., & Lang, C. C. (2008) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2008.00053.x · Cited by 51
Seino, Y., Nakajima, H., Miyahara, H., Kurita, T., Bush, M. A., Yang, F., Stewart, M. W., & For the Albiglutide Study Group (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903372999 · Cited by 45
Moritoh, Y., Takeuchi, K., Asakawa, T., Kataoka, O., & Odaka, H. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00145.x · Cited by 49
“…in response to nutrient ingestion and play an important role in glucose homeostasis by stimulating glucose-dependent insulin secretion (Vilsboll and Holst, 2004; Drucker, 2007) and exhibiting trophic effects on pancreatic b-cells (Farilla et al., 2002; Rolin et al., 2002; Perfetti and Hui, 2004).”
BackgroundUse of incretin agents and risk of pancreatic cancer: a population‐based cohort study
Knapen, L. M., van Dalem, J., Keulemans, Y. C., van Erp, N. P., Bazelier, M. T., De Bruin, M. L., Leufkens, H. G. M., Croes, S., Neef, C., de Vries, F., et al. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12605 · Cited by 43
Yu, W., Chen, Y., Hwang, P., Chen, T., & Chou, T. (2017) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201700136 · Cited by 45
Ectopic expression of glucagon-like peptide 1 for gene therapy of type II diabetes
Parsons, G. B., Souza, D. W., Wu, H., Yu, D., Wadsworth, S. G., Gregory, R. J., & Armentano, D. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302842 · Cited by 45
Glucagon-like peptide-1 receptor agonist treatment reduces beta cell mass in normoglycaemic mice
Ellenbroek, J. H., Töns, H. A. M., Westerouen van Meeteren, M. J. A., de Graaf, N., Hanegraaf, M. A., Rabelink, T. J., Carlotti, F., & de Koning, E. J. P. (2013) · Diabetologia · doi:10.1007/s00125-013-2957-2 · Cited by 43
“In animal models of diabetes these therapies increase beta cell mass [4–6].”
BackgroundTews, D., Werner, U., & Eckel, J. (2008) · Hormone and Metabolic Research · doi:10.1055/s-2008-1042426 · Cited by 43
Cairano, E. S. D., Moretti, S., Marciani, P., Sacchi, V. F., Castagna, M., Davalli, A. M., Folli, F. B., & Perego, C. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.25176 · Cited by 52
Koole, C., Savage, E. E., Christopoulos, A., Miller, L. J., Sexton, P. M., & Wootten, D. (2013) · Molecular Endocrinology · doi:10.1210/me.2013-1116 · Cited by 42
Picha, K. M., Cunningham, M. R., Drucker, D. J., Mathur, A. S., Ort, T., Scully, M. S., Soderman, A. R., Spinka-Doms, T., Stojanovic-Susulic, V., Thomas, B. A., et al. (2008) · Diabetes · doi:10.2337/db07-1775 · Cited by 41
Use of incretin agents and risk of acute and chronic pancreatitis: A population‐based cohort study
Knapen, L. M., de Jong, R. G. P. J., Driessen, J. H. M., Keulemans, Y. C. A., van Erp, N. P., Bruin, M. L. D., Leufkens, H. G. M., Croes, S., & de Vries, F. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12833 · Cited by 46
Functional importance of GLP-1 receptor species and expression levels in cell lines
Knudsen, L. B., Hastrup, S., Underwood, C. R., Wulff, B. S., & Fleckner, J. (2012) · Regulatory Peptides · doi:10.1016/j.regpep.2011.12.006 · Cited by 43
Chang, T., Tseng, H.-C., Liu, M.-W., Chang, Y., Hsieh, M.-L., & Chuang, L. (2016) · Scientific Reports · doi:10.1038/srep23403 · Cited by 48
β-Cell Death in Diabetes: Past Discoveries, Present Understanding, and Potential Future Advances
Mukherjee, N., Lin, L., Contreras, C., & Templin, A. T. (2021) · Metabolites · doi:10.3390/metabo11110796 · Cited by 49
Pleiotropic Actions of the Incretin Hormones
McIntosh, C. H. S., Widenmaier, S. B., & Kim, S. (2010) · Vitamins and hormones · doi:10.1016/b978-0-12-381517-0.00002-3 · Cited by 47
Talbot, J., Joly, E. C., Prentki, M., & Buteau, J. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.08.010 · Cited by 43
Impact of Sitagliptin on Markers of β-cell Function: A Meta-Analysis
Riche, D. M., East, H. E., & Riche, K. D. (2009) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31818eb721 · Cited by 44
Pancreatic β-cells expressing GLP-1 are resistant to the toxic effects of immunosuppressive drugs
D’Amico, E., Hui, H., Khoury, N., Mario, U. D., & Perfetti, R. (2005) · Journal of Molecular Endocrinology · doi:10.1677/jme.1.01655 · Cited by 46
Self-citationAydin, K., Arusoglu, G., Koksal, G., Cinar, N., Yazgan Aksoy, D., & Yildiz, B. O. (2014) · Clinical Endocrinology · doi:10.1111/cen.12468 · Cited by 39
Zhou, J., Wu, J., Zheng, F., Jin, M., & Li, H. (2014) · Journal of Diabetes · doi:10.1111/1753-0407.12177 · Cited by 42
“Furthermore, GLP-1 has been shown to prevent β-cell apoptosis in Zucker diabetic rats.(35) We also investigated the mechanisms underlying the protective effects of the GLP-1 analog liraglutide against cholesterol-induced apoptosis.”
BackgroundKimple, M. E., Moss, J. B., Brar, H. K., Rosa, T. C., Truchan, N. A., Pasker, R. L., Newgard, C. B., & Casey, P. J. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.359745 · Cited by 41
Weight Considerations in Pharmacotherapy for Type 2 Diabetes
Cheng, V., & Kashyap, S. R. (2010) · Journal of Obesity · doi:10.1155/2011/984245 · Cited by 46
“beta cell proliferation and inhibiting apoptosis [38].”
Chueire, V. B., & Muscelli, E. (2020) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000313 · Cited by 50
Yao, M., Zhang, J., Zhi-hong, L., Bai, X., Ma, J., & Li, Y. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.630962 · Cited by 47
Backes, B. J., Longenecker, K. L., Hamilton, G. L., Stewart, K. D., Lai, C., Kopecka, H., von Geldern, T. W., Madar, D. J., Pei, Z., Lubben, T. H., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.01.026 · Cited by 41
Campbell, R. K. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1h459 · Cited by 45
Glucagon-Like Peptide-1 Receptor Agonists for Diabetes Mellitus: A Role in Cardiovascular Disease
Smilowitz, N. R., Donnino, R. M., & Schwartzbard, A. Z. (2014) · Circulation · doi:10.1161/circulationaha.113.006985 · Cited by 44
“from pancreatic progenitor cells.(21) GLP-1 attenuates gastrointestinal secretions, mobility, and gastric emptying, and may have direct effects on the hypothalamus to decrease appetite, causing earlier satiety and promoting weight loss.”
Background
Metadata
- Authors
- Farilla, L., Hui, H., Bertolotto, C., Kang, E., Bulotta, A., Di Mario, U., & Perfetti, R.
- Affiliations
- Cedars-Sinai Medical Center (US)
- University of California, Los Angeles (US)
- Corresponding author
- Perfetti, Riccardo
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2002-11-01
- Volume
- 143
- Issue
- 11
- Pages
- 4397-4408
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2063693981
- Cited by
- 502
- References
- 20
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 5 · 2023: 10 · 2022: 5 · 2021: 17 · 2020: 12 · 2019: 18 · 2018: 12 · 2017: 16 · 2016: 18 · 2015: 25 · 2014: 32 · 2013: 33 · 2012: 33
- FWCI
- 17.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Federation for Aging Research
- Cedars-Sinai Medical Center
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- glucagon-like peptide-1, islet cell proliferation, beta-cell apoptosis, type 2 diabetes, insulin secretion, glucose tolerance, caspase-3, Ki-67, exocrine pancreas, pancreatic islets, nuclear fragmentation
- MeSH terms
- Insulin Secretion, Animals, Blood Glucose, Cell Division, Diabetes Mellitus, Glucagon, Insulin, Islets of Langerhans, Kinetics, Male, Peptide Fragments, Protein Precursors, Rats, Zucker, Apoptosis, Ki-67 Antigen, Caspases, In Situ Nick-End Labeling, Rats, Glucagon-Like Peptide 1, Caspase 3
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.